Cargando…

Highly Adaptable Triple-Negative Breast Cancer Cells as a Functional Model for Testing Anticancer Agents

A major obstacle in developing effective therapies against solid tumors stems from an inability to adequately model the rare subpopulation of panresistant cancer cells that may often drive the disease. We describe a strategy for optimally modeling highly abnormal and highly adaptable human triple-ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Balraj, Shamsnia, Anna, Raythatha, Milan R., Milligan, Ryan D., Cady, Amanda M., Madan, Simran, Lucci, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184880/ https://www.ncbi.nlm.nih.gov/pubmed/25279830 http://dx.doi.org/10.1371/journal.pone.0109487

Ejemplares similares

Selection of Metastatic Breast Cancer Cells Based on Adaptability of Their Metabolic State
por: Singh, Balraj, et al.
Publicado: (2012)

Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential
por: Singh, Balraj, et al.
Publicado: (2019)

Correction: Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential
por: Singh, Balraj, et al.
Publicado: (2022)

A usable model of “decathlon winner” cancer cells in triple-negative breast cancer: survival of resistant cancer cells in quiescence
por: Singh, Balraj, et al.
Publicado: (2018)

Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge
por: Singh, Balraj, et al.
Publicado: (2016)

Sensitization of Resistant Cells with a BET Bromodomain Inhibitor in a Cell Culture Model of Deep Intrinsic Resistance in Breast Cancer
por: Singh, Balraj, et al.
Publicado: (2023)

Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine
por: Singh, Balraj, et al.
Publicado: (2021)

Sensitization of Resistant Breast Cancer Cells with a Jumonji Family Histone Demethylase Inhibitor
por: Singh, Balraj, et al.
Publicado: (2022)

Potent Small-Molecule Inhibitors Targeting Acetylated Microtubules as Anticancer Agents Against Triple-Negative Breast Cancer
por: Kwon, Ahreum, et al.
Publicado: (2020)

Circulating tumor cells in non-metastatic triple-negative breast cancer
por: Karhade, Mandar, et al.
Publicado: (2014)

Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers
por: Addanki, Sridevi, et al.
Publicado: (2022)

The “Yin and Yang” of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers
por: Varghese, Elizabeth, et al.
Publicado: (2018)

Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer
por: Bahman, Fatemah, et al.
Publicado: (2021)

Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers
por: Gari, Hamid H., et al.
Publicado: (2016)

The Anticancer Effects of Flavonoids through miRNAs Modulations in Triple-Negative Breast Cancer
por: Adinew, Getinet M., et al.
Publicado: (2021)

Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells
por: Librizzi, Mariangela, et al.
Publicado: (2016)

The Anticancer Effects of FDI-6, a FOXM1 Inhibitor, on Triple Negative Breast Cancer
por: Ulhaka, Karan, et al.
Publicado: (2021)

Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair Deficiency
por: Liao, Gaoming, et al.
Publicado: (2022)

Combination of Talazoparib and Calcitriol Enhanced Anticancer Effect in Triple−Negative Breast Cancer Cell Lines
por: Wong, Fu Hou, et al.
Publicado: (2022)

Ceritinib is a novel triple negative breast cancer therapeutic agent
por: Dong, Shengli, et al.
Publicado: (2022)

Synthesis and Biological Evaluation of Novel Triple-Modified Colchicine Derivatives as Potent Tubulin-Targeting Anticancer Agents
por: Majcher, Urszula, et al.
Publicado: (2018)

Signal Transduction Inhibitors as Promising Anticancer Agents
por: Kumar, Raj, et al.
Publicado: (2015)

Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy
por: Feng, Tingting, et al.
Publicado: (2016)

Potentiation of the Anticancer Effects by Combining Docetaxel with Ku-0063794 against Triple-Negative Breast Cancer Cells
por: Jeon, Ye-Won, et al.
Publicado: (2022)

Flavonoids as Anticancer Agents
por: Kopustinskiene, Dalia M., et al.
Publicado: (2020)

Repurposing Tranexamic Acid as an Anticancer Agent
por: Law, Mary E., et al.
Publicado: (2022)

Anticancer agents : frontiers in cancer chemotherapy /
Publicado: (2001)

Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer
por: Mancini, Patrizia, et al.
Publicado: (2014)

Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment
por: Gao, Bowen, et al.
Publicado: (2021)

Stealth Liposomal Chemotherapeutic Agent for Triple Negative Breast Cancer with Improved Pharmacokinetics
por: Kommineni, Nagavendra, et al.
Publicado: (2022)

Biological Evaluation of Noscapine analogues as Potent and Microtubule-Targeted Anticancer Agents
por: Tomar, Vartika, et al.
Publicado: (2019)

Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance
por: Petruzzella, Emanuele, et al.
Publicado: (2018)

Iridoid Derivatives as Anticancer Agents: An Updated Review from 1970–2022
por: Ndongwe, Tanaka, et al.
Publicado: (2023)

The molecular mechanism of the anticancer effect of Artonin E in MDA-MB 231 triple negative breast cancer cells
por: Etti, Imaobong Christopher, et al.
Publicado: (2017)

Anticancer and Anti-Inflammatory Properties of Ganoderma lucidum Extract Effects on Melanoma and Triple-Negative Breast Cancer Treatment
por: Barbieri, Antonio, et al.
Publicado: (2017)

Current shreds of evidence on the anticancer role of EGCG in triple negative breast cancer: an update of the current state of knowledge
por: Bimonte, Sabrina, et al.
Publicado: (2020)

CSA Antisense Targeting Enhances Anticancer Drug Sensitivity in Breast Cancer Cells, including the Triple-Negative Subtype
por: Filippi, Silvia, et al.
Publicado: (2022)

SH003 and Docetaxel Show Synergistic Anticancer Effects by Inhibiting EGFR Activation in Triple-Negative Breast Cancer
por: Choi, Yu-Jeong, et al.
Publicado: (2022)

A Review of Metabolic Targets of Anticancer Nutrients and Nutraceuticals in Pre-Clinical Models of Triple-Negative Breast Cancer
por: Wiggs, Alleigh, et al.
Publicado: (2022)

DNA minicircles as novel STAT3 decoy oligodeoxynucleotides endowed with anticancer activity in triple-negative breast cancer
por: Casas, Geoffrey, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2vntiq8sapcr17qcic7kq8s1fd